Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort

Abstract

Background:

Onset of multiple sclerosis (MS) is typically in early adulthood. The impact, if any, of menopause on the MS course is unknown. Our objective was to determine whether menopause is associated with changes in MS severity in a longitudinal clinical cohort.

Methods:

Responses from an ongoing reproductive questionnaire deployed in all active female CLIMB observational study participants with a diagnosis of clinically isolated syndrome (CIS) or MS were analyzed when the response rate was 60%. Reproductive data were linked with clinical severity measures that were prospectively collected every six months, including our primary measure, the Expanded Disability Status Scale (EDSS).

Results:

Over one-half of the respondents (368 of 724 women) were postmenopausal. Median age at natural menopause was 51.5 years. In our primary analysis of 124 women who were followed longitudinally (mean duration 10.4 years) through their menopausal transition (natural or surgical), menopause represented an inflection point in their EDSS changes (difference of 0.076 units; 95% CI 0.010–0.14; p = 0.024). These findings were not explained by vitamin D levels, nor changes in treatment or smoking status over this period. There was no effect of hormone replacement therapy (HRT) exposure, but HRT use was low.

Conclusions:

We observed a possible worsening of MS disability after menopause. Larger cohorts are required to assess any HRT effects.

Keywords

Clinically isolated syndrome disability disease progression estrogen hormone replacement therapy menopause multiple sclerosis oophorectomy patient reported outcome quality of life

Get full access to this article

View all access options for this article.

References

Erel

Guralp

. Epilepsy and menopause. Arch Gynecol Obstet 2011; 284: 749–755.

Shulman

. Is there a connection between estrogen and Parkinson’s disease? Parkinsonism Relat Disord 2002; 8: 289–295.

Henderson

. The neurology of menopause. Neurologist 2006; 12: 149–159.

Rocca

Grossardt

Shuster

. Oophorectomy, menopause, estrogen treatment and cognitive aging: Clinical evidence for a window of opportunity. Brain Res 2011; 1379: 188–198.

Tutuncu

Tang

Zeid

. Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 2013; 19: 188–198.

Bove

Chitnis

. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler 2014; 20: 520–526.

Bove

Healy

Augustine

. Effect of gender on late-onset multiple sclerosis. Mult Scler 2012; 18: 1472–1479.

Clayton

Collins

. Policy: NIH to balance sex in cell and animal studies. Nature 2014; 509: 282–283.

Bove

Musallam

Healy

. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol 2013; 13: 73.

10.

Bove

Healy

Secor

. Patients report worse MS symptoms after menopause: Findings from an online cohort. Mult Scler Related Disord 2015; 4: 18–24.

11.

Holmqvist

Wallberg

Hammar

. Symptoms of multiple sclerosis in women in relation to sex steroid exposure. Maturitas 2006; 54: 149–153.

12.

Smith

Studd

. A pilot study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J Royal Soc Med 1992; 85: 612–613.

13.

Wundes

Amtmann

Brown

. Menopause in women with multiple sclerosis. Int J MS Care 2011; 13: 47.

14.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions tothe McDonald Criteria. Ann Neurol 2005; 58: 840–846.

15.

Harlow

Gass

Hall

. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97: 1159–1168.

16.

Shao

Breitner

Whitmer

. Hormone therapy and Alzheimer disease dementia: New findings from the Cache County Study. Neurology 2012; 79: 1846–1852.

17.

Kurtzke

. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.

18.

Fischer

Rudick

Cutter

. The Multiple Sclerosis Functional Composite Measure (MSFC): An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244–250.

19.

Hays

Anderson

Revicki

. Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 1993; 2: 441–449.

20.

Fisk

Ritvo

Ross

. Measuring the functional impact of fatigue: Initial validation of the Fatigue Impact Scale. Clin Infect Dis 1994; 18: S79–83.

21.

Radloff

. The CES-D Scale: A self-report depression scale for research in the general population. Appl Psycholog Meas 1977; 1: 385–401.

22.

Erel

Brincat

Gambacciani

. EMAS position statement: Managing the menopause in women with epilepsy. Maturitas 2010; 66: 327–328.

23.

Naumova

Must

Laird

. Tutorial in biostatistics: Evaluating the impact of ‘critical periods’ in longitudinal studies of growth using piecewise mixed-effects models. Int J Epidemiol 2001; 30: 1332–1341.

24.

Harward

Mitchell

Pieper

. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 2013; 22: 81–86.

25.

Healy

Engler

Glanz

. Assessment of definitions of sustained disease progression in relapsing–remitting multiple sclerosis. Mult Scler Int 2013; 2013: 189624.

26.

Spence

Voskuhl

. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol 2012; 33: 105–115.

27.

Bove

Secor

Chibnik

. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology 2014; 82: 222–229.

28.

Langer

Manson

Allison

. Have we come full circle - or moved forward? The Women’s Health Initiative 10 years on. Climacteric 2012; 15: 206–212.

29.

Cheng

Millen

Wactawski-Wende

. Vitamin D intake determines vitamin D status of postmenopausal women, particularly those with limited sun exposure. J Nutr 2014; 144: 681–689.

30.

Mowry

. Vitamin D: Evidence for its role as a prognostic factor in multiple sclerosis. J Neurol Sci 2011; 311: 19–22.

31.

Bove

Secor

Healy

. Evaluation of an online platform for multiple sclerosis research: Patient description, validation of severity scale and exploration of BMI effects on disease course. PLoS One 2013; 8: e59707.

32.

Gold

Bromberger

Crawford

. Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am J Epidemiol 2001; 153: 865–874.

33.

Alwan

Yee

Dybalski

. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler 2013; 19: 351–358.

34.

Hadjimichael

Vollmer

Oleen-Burkey

. Fatigue characteristics in multiple sclerosis: The North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008; 6: 100.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.43 MB

0.31 MB